Overview
RNAC market data
Price History
RNAC price chart · 1M
- O
- 10.04
- H
- 10.04
- L
- 9.86
- C
- 9.99
- Vol
- 2,843.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $10.04
- Previous Close
- $10.26
- Day High
- $10.04
- Day Low
- $9.86
- 52 Week High
- $10.88
- 52 Week Low
- $5.78
- 7 Day Return
- -2.68%
- 30 Day Return
- +30.50%
- 90 Day Return
- +32.85%
- 1 Year Return
- +54.40%
- Daily Notional Volume
- $28.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.66 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -8,550.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.60 – $11.39 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $267.9M · P/B 2.17 · P/S 150.94.
Company News
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price TargetBenzinga · Aug 18, 2026, 12:34 PM
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) EstimateBenzinga · Aug 6, 2026, 11:26 AM
8-K filing — Cartesian Therapeutics, Inc. (RNAC)SEC EDGAR · Aug 6, 2026, 11:03 AM
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease MarketBenzinga · Jun 9, 2026, 5:35 PM
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price TargetBenzinga · Jun 9, 2026, 5:00 PM
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price TargetBenzinga · Jun 9, 2026, 4:40 PM
Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone PaymentsBenzinga · Jun 9, 2026, 11:15 AM
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsightGlobenewswire Inc · Jun 2, 2026, 5:15 PM